Iniparib (BSI-201) 化学構造
分子量: 292.03





  • Compare PARP Inhibitors
  • 研究分野



製品説明 Iniparib (BSI-201)は一種のPARP1阻害剤で、三種陰性乳癌(TNBC)に作用効果を持っています。臨床3期。
In vitro試験 BSI-201 is described as a prodrug of 4-iodo-3-nitrosobenzamide, an agent that covalently inhibits PARP1 by binding to its first zinc finger under cell-free conditions. Treatment of 120 μM BSI-201 plus buthionine sulfoximine (BSO) induces a 95% cell death among 855-2 cells, and displays a similar effect in other human cancer cells. [1] BSI-201 inhibits the growth of E-ras 20 cells, the effect of which can be augmented 4-fold when BOS is added. [2] Recently BSI-201 shows no ability to inhibit PARP enzymatic or cellular activity, but can non-selectively modify cysteine-containing proteins in tumor cells, suggesting the mechanism of action for BSI-201 is likely not via inhibition of PARP activity. [3] BSI-201 (100 μM) inhibits ionizing radiation-induced single-strand breaks (SSBs) repair in human lymphoid cell lines based on large endogenous Epstein–Barr virus (EBV) circular episomes assay, resulting in 55% repair by 2 hours, which can be reversed surprisingly by knockdown of PARP1, indicating that the mechanism of inhibition does not involve trapping PARP at SSBs. [4] BSI-201 is not able to selectively kill homologous recombination (HR)-deficient cells between BRCA2-deficient PEO1 and BRCA2-revertant PEO4, or ATM-deficient GM16666 and ATM-restored GM16667 fibroblasts. BSI-201 is cytotoxic to a variety of cell lines at concentrations above 40 μM reflecting a mechanism independent of PARP. [5]
In vivo試験

プロトコル (参考用のみ)

細胞アッセイ: [3]

細胞株 MDA-MB-231, and MDA-MB-436
濃度 Dissolved in DMSO, final concentrations ~10 μM
反応時間 5, and 9 days
実験の流れ Cells are exposed to various concentrations of BSI-201 for 5, and 9 days in the presence or absence of buthionine sulfoxamide (BSO). After treatment, cell proliferation is measured by CellTiter-Glo assay.

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDogMonkeyBaboon
Weight (kg)
Body Surface Area (m2)0.0070.0250.
Km factor361285201220
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)



Download Iniparib (BSI-201) SDF
分子量 292.03


CAS No. 160003-66-7
保管 3年-20℃
2年-80℃in solvent
別名 NSC-746045, IND-71677
溶解度 (25°C) * In vitro DMSO 58 mg/mL (198.6 mM)
Ethanol 28 mg/mL (95.88 mM)
Water <1 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
化学名 4-iodo-3-nitrobenzamide

文献中の引用 (7)



電話番号: +1-832-582-8158 Ext:3月曜日〜金曜日 9:00 AM–5:00 PM (米国中部標準時)


* 必須

Related PARP 阻害剤

  • G007-LK

    G007-LKは一種の有効的で、選択性タンキラーゼ(tankyrase)阻害剤で、TNKS1/2に作用する時のIC50値が46 nM と 25 nMに分かれます。

  • NU1025

    NU1025は一種の有効なPARP阻害剤で、このIC50値が 400 nMです。

  • SCR7

    SCR7 is a specific DNA Ligase IV inhibitor, which blocks nonhomologous end-joining (NHEJ).

  • Blasticidin S HCl

    Blasticidin S HCl is a nucleoside antibiotic isolated from Stretomyces girseochromogenes, and acts as a DNA and protein synthesis inhibitor, used to select transfected cells carrying bsr or BSD resistance genes.

  • Olaparib (AZD2281, Ku-0059436)

    Olaparib (AZD2281, Ku-0059436)は一種の選択性PARP1/2阻害剤で、無細胞試験でIC50値が 5 nM/1 nMになって、PARP1/2に作用する効果は tankyrase-1に作用する効果が300倍が高くなります。臨床3期。

    Features:A potent PARP inhibitor (currently in late stage clinical trials).

  • Veliparib (ABT-888)

    Veliparib (ABT-888) は一種の有効なPARP1とPARP2阻害剤で、無細胞試験でKi値が5.2 nM と2.9 nMに分かれて、SIRT2に活性を表しません。臨床3期。

    Features:Increases the efficacy of common cancer therapies such as radiation and alkylating agents.

  • Rucaparib (AG-014699,PF-01367338)

    Rucaparib (AG-014699, PF-01367338)は一種のPARP阻害剤で、無細胞試験でPARP1に作用する時のKi値が1.4 nMになって、残り8つPARPドメインにも結合親和力を表します。臨床3期。

    Features:The first PARP inhibitor used in clinical trials combined with temozolomide.

  • Talazoparib (BMN 673)

    Talazoparib (BMN 673)は一種の新たなPARP阻害剤で、無細胞試験でIC50値が0.58 nMになります。Talazoparib (BMN 673)も一種の有効なPARP-2阻害剤ですが、PARGを抑制しなくて、PTEN突然変異型に高度敏感をしています。臨床3期。

    Features:Most potent and selective PARPi reported thus far.

  • PJ34 HCl

    PJ34 HClはPJ34の塩酸塩形式で、一種のPARP阻害剤です。PJ34 HClはEC50値が20 nMになって、 PARP1/2に同等有効に作用します。

    Features:Water-soluble PARP1/2 inhibitor with >10,000-fold potentcy vs. 3-aminobenzamide (prototypical PARP inhibitor). Potential uses in cardiovascular diseases (stroke, cerebral ischemia, & myocardial ischemia).


Tags: Iniparib (BSI-201)を買う | Iniparib (BSI-201)供給者 | Iniparib (BSI-201)を購入する | Iniparib (BSI-201)費用 | Iniparib (BSI-201)生産者 | オーダーIniparib (BSI-201) | Iniparib (BSI-201)代理店
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID